А. М. Гуськов
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
А. М. Гуськов has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- L. A. Gaiderova
Scientific Centre for Expert Evaluation of Medicinal Products
3 shared publications - Наталья Александровна Алпатова
Scientific Centre for Expert Evaluation of Medicinal Products
3 shared publications - O. V. Golovinskaya
Scientific Centre for Expert Evaluation of Medicinal Products
2 shared publications - S. L. Lysikova
Scientific Centre for Expert Evaluation of Medicinal Products
2 shared publications - D. A. Zubkov
Scientific Centre for Expert Evaluation of Medicinal Products
1 shared publication - E. K. Lipatova
Scientific Centre for Expert Evaluation of Medical Product
1 shared publication
Latest Publications
- Open Access
- 24 June 2025
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 13 (2) , 229-239
Implementation of the 3Rs Concept in Quality Control of Biologicals: Status and Prospects (Review)
INTRODUCTION. Many countries are implementing an increasing number of alternatives to animal testing in the research, development, and quality control of medicines under the concept of 3Rs (replacement, reduction, and refinement). However, the implementation of in vitro alternatives to in vivo methods into batch release testing of biologicals, primarily vaccines, is a challenging process. The introduction of the 3Rs principles into regulatory and industry standards requires a comprehensive analysis, including, among other things, a study of specific considerations for national frameworks.AIM. This study aimed to analyse the degree of global integration of the 3Rs principles in the quality control of biological medicinal products and to assess existing challenges and opportunities for a successful transition to non-animal quality control methods in the Russian Federation.DISCUSSION. The key advantages of in vitro biological methods over in vivo approaches for quality control of medicinal products include reduced variability, higher specificity, and shorter testing timelines. Analysis of assessments by regulatory authorities and pharmaceutical manufacturers regarding the opportunities and challenges in implementing the 3Rs principles has identified the following main arguments for replacing in vivo methods: ethical considerations, relevance of reducing testing time, decreased variability. The integration of in vitro methods is hindered by insufficient information on alternative approaches and the lack of harmonised regulatory frameworks for adopting 3Rs principles. For instance, the European Pharmacopoeia has eliminated all general safety testing of biological medicinal products in animals as part of its 3Rs implementation. Furthermore, the World Health Organization has developed guidelines for the phased discontinuation of animal testing in the quality control of biological products.CONCLUSIONS. The main challenges associated with 3Rs implementation include the difficulty of confirming the in vitro – in vivo correlation (particularly, by comparing in vivo and in vitro methods), the lack of regulatory harmonisation, and the insufficient regulatory support for manufacturers in adopting alternative methods. The international harmonisation of regulatory requirements is necessary to effectively address these issues and successfully implement the 3Rs principles in the quality control procedures for biologicals released in different countries, including the Russian Federation.
- 24 June 2025
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 13 (2) , 229-239
Open AccessImplementation of the 3Rs Concept in Quality Control of Biologicals: Status and Prospects (Review)
INTRODUCTION. Many countries are implementing an increasing number of alternatives to animal testing in the research, development, and quality control of medicines under the concept of 3Rs (replacement, reduction, and refinement). However, the implementation of in vitro alternatives to in vivo methods into batch release testing of biologicals, primarily vaccines, is a challenging process. The introduction of the 3Rs principles into regulatory and industry standards requires a comprehensive analysis, including, among other things, a study of specific considerations for national frameworks.AIM. This study aimed to analyse the degree of global integration of the 3Rs principles in the quality control of biological medicinal products and to assess existing challenges and opportunities for a successful transition to non-animal quality control methods in the Russian Federation.DISCUSSION. The key advantages of in vitro biological methods over in vivo approaches for quality control of medicinal products include reduced variability, higher specificity, and shorter testing timelines. Analysis of assessments by regulatory authorities and pharmaceutical manufacturers regarding the opportunities and challenges in implementing the 3Rs principles has identified the following main arguments for replacing in vivo methods: ethical considerations, relevance of reducing testing time, decreased variability. The integration of in vitro methods is hindered by insufficient information on alternative approaches and the lack of harmonised regulatory frameworks for adopting 3Rs principles. For instance, the European Pharmacopoeia has eliminated all general safety testing of biological medicinal products in animals as part of its 3Rs implementation. Furthermore, the World Health Organization has developed guidelines for the phased discontinuation of animal testing in the quality control of biological products.CONCLUSIONS. The main challenges associated with 3Rs implementation include the difficulty of confirming the in vitro – in vivo correlation (particularly, by comparing in vivo and in vitro methods), the lack of regulatory harmonisation, and the insufficient regulatory support for manufacturers in adopting alternative methods. The international harmonisation of regulatory requirements is necessary to effectively address these issues and successfully implement the 3Rs principles in the quality control procedures for biologicals released in different countries, including the Russian Federation.
- Open Access
- 22 December 2024
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 24 (4) , 443-455
Potency evaluation of erythropoietin products: current status
INTRODUCTION. Given the widespread clinical use of recombinant human erythropoietin (rhEPO) products from different manufacturers, potency assays should ensure that patients receive comparable doses of rhEPO across medicinal products. The harmonisation of approaches to potency testing requires the use of pharmacopoeial bioassays and appropriate international/pharmacopoeial reference standards (RSs).AIM. This study aimed to summarise information on pharmacopoeial requirements, relevant RSs, and bioassays (in vivo and in vitro) for the assessment of rhEPO potency, as well as to analyse the pharmacopoeial compliance of manufacturers’ specifications for rhEPO products authorised in Russia.DISCUSSION. This article presents information on the molecular structure of erythropoietin. The glycosylation profile of erythropoietin not only accounts for most of the differences in the half-life and biodegradation rate but also significantly influences the potency of rhEPO products. The authors outlined the pharmacopoeial requirements for potency assays in vivo, summarised the information on RSs for potency determination, characterised the development of potency assays in vitro, and studied the possibility of including in vitro assays in pharmacopoeias. The analysis showed that some potency assays used for rhEPO products manufactured in Russia did not comply with the requirements of the State Pharmacopoeia of the Russian Federation.CONCLUSIONS. The study identified the need to develop and certify a national pharmacopoeial RS for the potency of rhEPO in order to satisfy the demands of Russian manufacturers in the context of import substitution. To implement adequate 3R-compliant methods for rhEPO quality assessment, it is necessary to harmonise approaches to potency testing of rhEPO products and develop a consolidated document governing such testing.
- 22 December 2024
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 24 (4) , 443-455
Open AccessPotency evaluation of erythropoietin products: current status
INTRODUCTION. Given the widespread clinical use of recombinant human erythropoietin (rhEPO) products from different manufacturers, potency assays should ensure that patients receive comparable doses of rhEPO across medicinal products. The harmonisation of approaches to potency testing requires the use of pharmacopoeial bioassays and appropriate international/pharmacopoeial reference standards (RSs).AIM. This study aimed to summarise information on pharmacopoeial requirements, relevant RSs, and bioassays (in vivo and in vitro) for the assessment of rhEPO potency, as well as to analyse the pharmacopoeial compliance of manufacturers’ specifications for rhEPO products authorised in Russia.DISCUSSION. This article presents information on the molecular structure of erythropoietin. The glycosylation profile of erythropoietin not only accounts for most of the differences in the half-life and biodegradation rate but also significantly influences the potency of rhEPO products. The authors outlined the pharmacopoeial requirements for potency assays in vivo, summarised the information on RSs for potency determination, characterised the development of potency assays in vitro, and studied the possibility of including in vitro assays in pharmacopoeias. The analysis showed that some potency assays used for rhEPO products manufactured in Russia did not comply with the requirements of the State Pharmacopoeia of the Russian Federation.CONCLUSIONS. The study identified the need to develop and certify a national pharmacopoeial RS for the potency of rhEPO in order to satisfy the demands of Russian manufacturers in the context of import substitution. To implement adequate 3R-compliant methods for rhEPO quality assessment, it is necessary to harmonise approaches to potency testing of rhEPO products and develop a consolidated document governing such testing.
- Open Access
- 17 December 2023
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 23 (4) , 480-498
International standards for monoclonal antibodies for assessing the biological activity of medicines: A status update
Scientific relevance. The clinical effects and the expiration of patents for original (reference) biotechnological medicines based on monoclonal antibodies (mAbs) stimulated the development of biosimilar mAbs. The quality profile of a biosimilar mAb should correspond to the quality of the reference medicinal product. When demonstrating biosimilarity and determining the activity of medicines as part of batch quality control, analysts should study the biological properties of mAbs using suitable reference standards. The lack of international standards (ISs) makes mAb manufacturers use in-house reference standards. There is a risk of obtaining non-uniform quality and efficacy data because of the use of in-house reference standards, the heterogeneity and structural complexity of mAbs, and the relationship between the biological activity and efficacy of mAbs.Aim. This study aimed to analyse the relevance of and need for ISs for the biological activity of biotherapeutic mAbs and to define the role of reference medicinal products and ISs in assessing biosimilarity and testing medicines throughout their lifecycle.Discussion. This review covers the issues arising from the lack of ISs for assessing the biological activity of mAbs and the role and significance of reference products and ISs for biosimilars. The authors describe the specifics of studying the biological properties of mAbs and summarise the data on the need to develop and use ISs for the standardisation of biological tests. This review presents the results of studies on the first ISs established by the World Health Organisation to assess the biological activity of mAbs; these results suggest the need to standardise mAbs using ISs to ensure the quality, safety, and efficacy of mAb therapy.Conclusions. The use of ISs for mAbs plays a key role in harmonising biological activity assessments. Publicly available ISs serve as primary standards for the calibration of secondary reference materials. Moreover, ISs are required for the harmonisation of activity evaluation (in IU) between laboratories and for the consistency of the activity of various medicinal products from different manufacturers that share the same INN. The use of ISs by mAb manufacturers will contribute to ensuring the quality of mAbs and clinical monitoring of the effectiveness of their use.
- 17 December 2023
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 23 (4) , 480-498
Open AccessInternational standards for monoclonal antibodies for assessing the biological activity of medicines: A status update
Scientific relevance. The clinical effects and the expiration of patents for original (reference) biotechnological medicines based on monoclonal antibodies (mAbs) stimulated the development of biosimilar mAbs. The quality profile of a biosimilar mAb should correspond to the quality of the reference medicinal product. When demonstrating biosimilarity and determining the activity of medicines as part of batch quality control, analysts should study the biological properties of mAbs using suitable reference standards. The lack of international standards (ISs) makes mAb manufacturers use in-house reference standards. There is a risk of obtaining non-uniform quality and efficacy data because of the use of in-house reference standards, the heterogeneity and structural complexity of mAbs, and the relationship between the biological activity and efficacy of mAbs.Aim. This study aimed to analyse the relevance of and need for ISs for the biological activity of biotherapeutic mAbs and to define the role of reference medicinal products and ISs in assessing biosimilarity and testing medicines throughout their lifecycle.Discussion. This review covers the issues arising from the lack of ISs for assessing the biological activity of mAbs and the role and significance of reference products and ISs for biosimilars. The authors describe the specifics of studying the biological properties of mAbs and summarise the data on the need to develop and use ISs for the standardisation of biological tests. This review presents the results of studies on the first ISs established by the World Health Organisation to assess the biological activity of mAbs; these results suggest the need to standardise mAbs using ISs to ensure the quality, safety, and efficacy of mAb therapy.Conclusions. The use of ISs for mAbs plays a key role in harmonising biological activity assessments. Publicly available ISs serve as primary standards for the calibration of secondary reference materials. Moreover, ISs are required for the harmonisation of activity evaluation (in IU) between laboratories and for the consistency of the activity of various medicinal products from different manufacturers that share the same INN. The use of ISs by mAb manufacturers will contribute to ensuring the quality of mAbs and clinical monitoring of the effectiveness of their use.